Invivo Therapeutics Holdings Corp (NVIV) Downgraded by ValuEngine
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
Separately, Raymond James Financial, Inc. reiterated an “outperform” rating and issued a $6.00 target price (down previously from $10.00) on shares of Invivo Therapeutics Holdings Corp in a report on Friday, May 5th.
Shares of Invivo Therapeutics Holdings Corp (NVIV) traded up 9.30% on Friday, hitting $2.35. 387,037 shares of the stock were exchanged. The stock’s 50-day moving average is $3.00 and its 200-day moving average is $4.05. The stock’s market cap is $75.56 million. Invivo Therapeutics Holdings Corp has a 1-year low of $1.90 and a 1-year high of $7.94.
Invivo Therapeutics Holdings Corp Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Invivo Therapeutics Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.